Johnson & Johnson Faces Class-Action Lawsuit Over Benzene-Tainted Neutrogena and Aveeno Sunscreen Products

- Pharmaceutical product-safety lawyers at the Beasley Allen law firm have filed a federal class-action lawsuit on behalf of consumers who bought recalled benzene-tainted sunscreen products made by Johnson & Johnson (NYSE: JNJ) subsidiaries Neutrogena and Aveeno.

The lawsuit seeks an injunction and damages on behalf of consumers who purchased a range of Neutrogena and Aveeno sun-care products. An analysis by independent lab Valisure found alarming concentrations of benzene in at least 78 sun-care products made by Neutrogena, CVS Health, Banana Boat and other manufacturers.

"It should not have taken the publication of a third party's tests to bring this critically important information to the public, and J&J's response so far is not enough. We will find out how long J&J knew about these concerns and why it took so long to take action," said product safety trial lawyer Andy Birchfield of the Beasley Allen law firm .

More than seven weeks after the lab results were published, Johnson & Johnson announced a recall of five spray products and ordered retailers to stop selling Neutrogena's sunscreens labeled Beach Defense, Cool Dry Sport, Invisible Daily, Ultra Sheer and Aveeno Protect + Refresh.

The Food and Drug Administration permits traces of benzene on rare occasions in medical products that are deemed critical, but the chemical is not allowed in sun-care products in any amount. The National Institute for Occupational Safety and Health (NIOSH) recommends protective equipment for those expecting to be exposed to benzene at concentrations above 0.1 parts per million for 10 hours or 1 ppm for 15 minutes. Some Neutrogena products contained benzene amounts of more than 6 ppm, according to Valisure.

While Valisure found benzene in both aerosol and lotion products, J&J's voluntary recall is limited to spray products. A full list of the risky sunscreens can be found here .

"When these kinds of safety failures occur, the American public deserves a swift and transparent accounting of what happened and what is being done to ensure it doesn't happen again," said Beasley Allen attorney David Byrne . "J&J's response falls far short of that."

The lawsuit Johanna Dominguez and Sharron Meijer et al. v. Johnson & Johnson Consumer Inc., is filed in the U.S. District Court for the Northern District of California , No. 3:21-CV-05419. In addition to Beasley Allen, the legal team includes Walsh Law PLLC and Keller Lenkner LLC.

Benzene is a common industrial chemical that has long been linked to leukemia, a deadly form of blood cancer. The discovery raises grave concerns because chemicals in sunscreen are known to be absorbed through the skin into the bloodstream – even after only one application. Since children's skin is more permeable than adults, the threat of absorption of harmful chemicals is even greater for them.

About the Beasley Allen Law Firm
Headquartered in Montgomery, Alabama , Beasley Allen is a national leader in medical product liability litigation, with a staff of experienced attorneys and expert staff committed to ensuring the safety of consumer and medical products. For more information, visit https://factsaboutsunscreen.com/ .

Media Contact :
Robert Tharp
800-559-4630
Robert@androvett.com

Cision View original content: https://www.prnewswire.com/news-releases/johnson--johnson-faces-class-action-lawsuit-over-benzene-tainted-neutrogena-and-aveeno-sunscreen-products-301335040.html

SOURCE Beasley Allen Law Firm

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Seegnal (TSXV:SEGN)

Seegnal Presents Real-World Evidence on Reducing Fall Risk in Geriatric Patients at Caltcm Summit

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in AI-enhanced prescription intelligence, today announced real-world clinical results demonstrating how medication governance may reduce fall-risk drivers in older adults -- a significant clinical and financial challenge... Keep Reading...
Scientists working in a modern medical research laboratory.

Pathways to Commercialising Biotech Innovations

In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at... Keep Reading...
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the... Keep Reading...
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries CommenceDownload the PDF here. Keep Reading...
Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities. The groundbreaking developments in antifungal treatments specifically targeting women's health issues... Keep Reading...

Interactive Chart

Latest Press Releases

Related News